The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
81
Active, Oral, 15 mg, Daily, 28 days
Active, Oral, 50 mg, Daily, 28 days
Active, Oral, 150 mg, Daily, 28 days
Harrell, Robert
Little Rock, Arkansas, United States
Cetero Research - San Antonio
San Antonio, Texas, United States
Local Institution
Blacktown, New South Wales, Australia
Lowering of LDL-C
Time frame: Within 28 days following dosing
Pharmacokinetics (Blood Level) of BMS-770767
Time frame: Within 28 days following dosing
Pharmacodynamic effects of BMS-770767 on Total cholesterol, HDL-C, Triglycerides, non-HDL-C, non-esterified free fatty acids, Apolipoprotein fractions, HPA axis marker and free testosterone and sex hormone binding globulin (SHBG)
Time frame: Within 28 days following dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Active, Oral, 50 mg BID, Daily, 28 days
Placebo, Oral, 0 mg, daily, 28 days
Local Institution
Hornsby, New South Wales, Australia
Local Institution
Caboolture, Queensland, Australia
Local Institution
South Brisbane, Queensland, Australia
Local Institution
Daw Park, South Australia, Australia
Local Institution
Nedlands, Western Australia, Australia
Local Institution
Bathurst, New Brunswick, Canada
Local Institution
Brampton, Ontario, Canada
...and 4 more locations